# Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

> **NCT00990587** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 20 (actual)

## Conditions studied

- Hematologic Malignancy
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Myelodysplasia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia
- Hodgkin's Disease

## Interventions

- **DRUG:** Ciclopirox Olamine

## Key facts

- **NCT ID:** NCT00990587
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-05
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990587, "Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00990587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*